This is not the latest version of this item. The latest version can be found here.
Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study
Name
nutrients-13-01760-v2.pdf
Size
1.07 MB
Format
Adobe PDF
Checksum (MD5)
4a232bb1b9440ccb13bb49187176f532
Author(s)
Alcala-Diaz, Juan F.
Limia-Perez, Laura
Gomez-Huelgas, Ricardo
Martin-Escalante, Maria D.
Cortes-Rodriguez, Begoña
Zambrana-Garcia, Jose L.
Entrenas-Castillo, Marta
Perez-Caballero, Ana I.
López-Carmona, Maria D.
Garcia-Alegria, Javier
Date Issued
May 21, 2021
Publisher
Multidisciplinary Digital Publishing Institute
Citation
Nutrients 13 (6): 1760 (2021)
Version
Final published version
Abstract
Context. Calcifediol has been proposed as a potential treatment for COVID-19 patients. Objective: To compare the administration or not of oral calcifediol on mortality risk of patients hospitalized because of COVID-19. Design: Retrospective, multicenter, open, non-randomized cohort study. Settings: Hospitalized care. Patients: Patients with laboratory-confirmed COVID-19 between 5 February and 5 May 2020 in five hospitals in the South of Spain. Intervention: Patients received calcifediol (25-hydroxyvitamin D3) treatment (0.266 mg/capsule, 2 capsules on entry and then one capsule on day 3, 7, 14, 21, and 28) or not. Main Outcome Measure: In-hospital mortality during the first 30 days after admission. Results: A total of 537 patients were hospitalized with COVID-19 (317 males (59%), median age, 70 years), and 79 (14.7%) received calcifediol treatment. Overall, in-hospital mortality during the first 30 days was 17.5%. The OR of death for patients receiving calcifediol (mortality rate of 5%) was 0.22 (95% CI, 0.08 to 0.61) compared to patients not receiving such treatment (mortality rate of 20%; p < 0.01). Patients who received calcifediol after admission were more likely than those not receiving treatment to have comorbidity and a lower rate of CURB-65 score for pneumonia severity ≥ 3 (one point for each of confusion, urea > 7 mmol/L, respiratory rate ≥ 30/min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years), acute respiratory distress syndrome (moderate or severe), c-reactive protein, chronic kidney disease, and blood urea nitrogen. In a multivariable logistic regression model, adjusting for confounders, there were significant differences in mortality for patients receiving calcifediol compared with patients not receiving it (OR = 0.16 (95% CI 0.03 to 0.80). Conclusion: Among patients hospitalized with COVID-19, treatment with calcifediol, compared with those not receiving calcifediol, was significantly associated with lower in-hospital mortality during the first 30 days. The observational design and sample size may limit the interpretation of these findings.
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
http://dx.doi.org/10.3390/nu13061760
